



LKT Laboratories, Inc.

RDEA119

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID R1217

CAS No. 923032-37-5

Chemical Name Refametinib

Synonym Refametinib, BAY 869766; N-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-cyclopropanesulfonamide; BAY 869766; BAY 8697661

Formula C₁₉H₂₀F₃I N₂O₅S

Formula Wt. 572.34

Melting Point

Purity ≥98%

Solubility DMSO 100 mg/mL (174.72 mM)


Ethanol 100 mg/mL (174.72 mM)

Water Insoluble

Store Temp -20°C

Ship Temp Ambient

Description RDEA119 inhibits MEK1/2 and exhibits anticancer chemotherapeutic activity. RDEA119 is currently in clinical trials as a potential treatment for a variety of advanced cancers. This compound inhibits proliferation in thyroid cancer cells, including those containing V600E B-Raf mutations. RDEA119 also inhibits tumor growth in animal models of melanoma, colon cancer, and epidermal carcinoma.



Bulk quantities available upon request

Product ID	Size
R1217	1 mg
R1217	5 mg
R1217	10 mg

References Weekes CD, Von Hoff DD, Adjei AA, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PMID: 23434733.

Liu D, Xing J, Trink B, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275.

Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.